The drug is Ambroxol. It’s been used for decades to treat respiratory ailments by thinning mucus and easing coughs. But now, ...

A decades-old cough medicine, Ambroxol, could be on the verge of a dramatic second act—not for sore throats, but for ...

An active ingredient in cough medicines since 1979 has shown promise as a treatment for neuropsychiatric symptoms in ...

Ambroxol, long used for coughs in Europe, stabilized symptoms and brain-damage markers in Parkinson’s dementia patients over 12 months, whereas placebo patients worsened. Those with high-risk ...

Today’s cough syrup could turn into tomorrow’s treatment for Parkinson’s disease. Recent research in the U.K. is the latest to suggest that a common ingredient in cough syrup, ambroxol, might be able ...

Ambroxol supports a key enzyme called glucocerebrosidase (GCase), which is produced by the GBA1 gene. In people with Parkinson's disease, GCase levels are often low.

Ambroxol supports a key enzyme called glucocerebrosidase (GCase), which is produced by the GBA1 gene. In people with Parkinson’s disease, GCase levels are often low.

Ambroxol boosts levels of an enzyme called GCase, which is known to help clear away waste products which have gathered in brain cells. In Parkinson’s, a build up of a troublesome protein called ...

Ambroxol, a common cough medicine used in Europe, demonstrated target engagement in people with Parkinson's disease dementia but did not show an effect on cognition compared with placebo, a year ...

“Ambroxol was safe, well-tolerated, and demonstrated target engagement,” scientists wrote, however adding that the drug’s clinical effect on cognition was “not confirmed” in the study.

Ambroxol supports a key enzyme called glucocerebrosidase (GCase), which is produced by the GBA1 gene. In people with Parkinson's disease, GCase levels are often low.

Ambroxol was safe, well-tolerated and reached therapeutic levels in the brain. Psychiatric symptoms worsened in the placebo group but remained stable in those taking Ambroxol.